New drug DS9051b enters first human tests for hard-to-treat cancers

NCT ID NCT07189403

Recruiting now Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-stage trial tests a new drug called DS9051b in about 40 adults with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for signs that the drug shrinks tumors. Participants must have tried other treatments first and be in fairly good health.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Brown University
RECRUITING

Providence, Rhode Island, 02903, United States

Contact
Centre Oscar Lambret
NOT_YET_RECRUITING

Villejuif, 94800, France

Contact
Columbia University
NOT_YET_RECRUITING

New York, New York, 10032, United States

Contact
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States

Contact
Oncopole Claudius Regaud
RECRUITING

Toulouse, 31100, France

Contact
Royal Marsden
NOT_YET_RECRUITING

London, SW3 6JJ, United Kingdom

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER